1. Tata Steel:

ICICI Securities maintains its ‘Buy’ rating on this steel company and raises the target price to Rs 190, indicating an upside of 19%. Tata Steel’s EBITDA/tonne increased by Rs 1,000 QoQ in Q4FY25, up from Rs 600, due to higher selling prices and lower fixed costs.

In Q4FY25, sales volume grew 3.3% YoY to 5.6 million tonnes, driven by higher production at the Odisha facility. Tata Steel Netherlands (TSN) reported a profit of Rs 120 crore in Q4FY25, compared to a loss in the same quarter last year.

Analysts Amit Dixit and Mohit Lohia expect Tata Steel’s overall EBITDA to grow 47% to Rs 37,100 crore in FY26, driven by improvements in the UK business. They also expect profits to rise in Q1FY26 due to higher selling prices of Rs 3,000 per tonne in India and a reduction of fixed costs by Rs 1,800-2,000 per tonne.

The management aims to reduce fixed costs by Rs 11,500 crore by FY27 across India, UK, and Netherlands operations. It expects cost reductions to help its Netherlands and the UK businesses break even by Q2FY26. The company plans to invest Rs 15,000 crore in capital expenditure in FY26 and reduce debt by Rs 3,000 crore.

2. V-Guard Industries:

Anand Rathi retains its ‘Buy’ rating on this electrical appliance company with a target price of Rs 475, indicating an upside potential of 25.1%. The company’s Q4FY25 revenue rose 14.5% YoY to Rs 1,538.1 crore, driven by strong growth in the electrical and electronics segments. Net profit grew 19.6% to Rs 91.1 crore due to lower interest costs.

Analyst Prasheel Gandhi expects the company’s electronics vertical to maintain strong momentum, led by stabilizers, inverter batteries, and the solar rooftop segment. He anticipates the solar rooftop business will contribute significant revenue over the next 4–5 years.

V-Guard Industries’ battery business revenue grew in double digits YoY in FY25. The management aims to increase battery capacity with an investment of Rs 50 crore and expects a revenue potential of Rs 300–400 crore in 2.5 years. The analysts project the company’s revenue and net profit to grow at a CAGR of 14.2% and 28.8%, respectively, over FY26–27.

3. Bank of Baroda:

Sharekhan maintains a ‘Buy’ rating on this bank with a target price of Rs 260, indicating an upside of 10%. In Q4FY25, Bank of Baroda’s net profit rose 3.3% YoY to Rs 5,048 crore. Treasury gains more than doubled to Rs 1,559 crore, supporting overall profitability and pushing return on assets (RoA) to around 1.2%. The analysts said, “We believe the bank is likely to sustain RoAs at ~1.0% in FY26 led by recoveries and higher treasury gains.”

Net interest income (NII) declined 7% YoY in Q4FY25, while net interest margin (NIM) fell by 33 basis points due to lower loan yields and higher cost of funds. The analysts believe the pressure on NIMs and asset quality volatility can be managed through recoveries, treasury gains, and a better mix of loans and deposits. They also highlighted the bank’s focus on growing current account savings account (CASA) and retail term deposits, while cutting back on bulk deposits to support long-term growth.

The bank’s gross non-performing assets (NPA) fell 10 bps YoY to 2.3% in the quarter. Analysts expect NII and net profit to grow by 8.5% and 2.8% over FY26–27, aided by stable asset quality.

4. Vijaya Diagnostic Center:

Emkay reiterates its ‘Buy’ rating on this healthcare services provider chain with a target price of Rs 1,150, indicating an upside of 24.6%. Analysts Anshul Agrawal and Abin Benny believe the next 2–3 years look promising, supported by the timely commissioning of new labs in non-core geographies (such as Pune, Kolkata) and management’s guidance of over 15% sales CAGR during FY26–28, despite the asset-heavy model.

In Q4FY25, Vijaya Diagnostic’s revenue rose 12% YoY to Rs 173 crore, led by a 20% growth in the wellness segment, which contributed 15% of total revenue. However, the EBITDA margin declined by 90 bps YoY to 39.8% due to expansion-related costs. Agrawal and Benny expect margins to improve to 40.5% by FY28, backed by the management’s target to achieve breakeven within 12 months for each new lab.

The company has commissioned two new labs in Q1FY26 and plans to add three more in the next 3–4 months. Analysts believe growth will also be supported by the management’s plan to increase prices by 1–2% across various test categories during FY26.

5. Blue Jet Healthcare:

Motilal Oswal reiterates its ‘Buy’ rating on this pharma company with a target price of Rs 965, implying an upside of 21%. In Q4FY25, the company’s revenue grew 85.1% YoY to Rs 3,404 crore, driven by higher sales in pharmaceutical intermediates. Net profit rose 177% to Rs 1,101 crore, helped by new capacity additions and improved plant efficiency.

Blue Jet's capex for FY25 stood at Rs 300 crore on research and development (R&D) and expansion of production capacity. Analysts Aman Chowdhary and Sumant Kumar expect strong revenue visibility in FY26, driven by rising demand for pharma intermediates and active pharmaceutical ingredients (APIs). They project the revenue share from the pharma intermediates to rise to 25% by FY27, up from 17% in FY25, aided by expansion into new markets such as Canada, the US, and Europe.

Analysts expect strong revenue growth from the API segment in FY26, driven by new product launches and increased production capacity. They project Blue Jet’s revenue and net profit to grow at a CAGR of 27% and 25%, respectively, over FY26–27.
 

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)